Clinical Oncology
Volume 20, Issue 4 , Pages 318-319 , May 2008

Severe Epistaxis with Tyrosine Kinase Inhibitors

References 

  1. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124
  2. Demetri G, vanOsterom A, Garrett R, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329–1338
  3. Pfizer. Manufacturer product information on Sutent, 2007.
  4. Bayer . Prescribing information. Available from: http://www.nexavar.com/wt/page/index
  5. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96:1788–1795
  6. Osusky K, Hallahan D, Fu A, et al. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumour vessels. Angiogenesis. 2004;7:225–233
  7. Vinogradov M, Moualla H, Liles DK, et al. Acquired factor VIII inhibitor in a patient treated with sunitinib. J Immunother. 2006;29:674

PII: S0936-6555(08)00059-9

doi: 10.1016/j.clon.2008.02.001

Clinical Oncology
Volume 20, Issue 4 , Pages 318-319 , May 2008

Article Tools